Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Conditions: Breast Cancer Interventions: Drug: AIs; Drug: OFS+AIs; Drug: FUL Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Factors Influencing Adherence to Adjuvant Endocrine Therapy
Conditions: Adherence, Treatment Interventions: Drug: Survey using a questionnaire. Sponsors: University of Zagreb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
Conditions: Advanced Breast Cancer; Treatment; HR Low/HER2 Negative Interventions: Drug: Experimental: chemotheyapy; Drug: Active Comparator: endocrine therapy Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg ® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Conditions: HR+HER2- Advanced Breast Cancer Interventions: Other: Ribociclib; Other: Combination chemotherapy Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Adebrelimab; Drug: dalpiciclib Sponsors: Tongji Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
Conditions: Breast Cancer Interventions: Procedure: core needle biopsy; Other: blood draw Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Conditions: Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Aromatase inhibitor; Drug: Docetaxel injection; Drug: Epirubicin Hydrochloride Injection; Drug: Cyclophosphamide injection Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
REDucing Hot FLASHes in Women Using Endocrine Therapy.
Conditions: Breast Cancer; Hot Flash Due to Medication Interventions: Drug: Oxybutynin; Drug: Venlafaxine Sponsors: Reinier de Graaf Groep Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol
DiscussionThis multisite study will not only define strategies to improve adherence to breast cancer oral therapies, but it will also potentially support strategies in large cooperative research groups that can increase delivery and tolerability of ET, involve diverse patient populations in clinical research, and engage patients effectively in interventional studies, using remote and cost-effective delivery methods.Trial registrationClinicaltrials.govNCT04379570. Registered on 7 May 2020. (Source: Trials)
Source: Trials - October 12, 2023 Category: Research Source Type: clinical trials
Biomarkers to Detect Endocrine Therapy Resistance
Conditions: Metastatic Cancer; Breast Cancer; Lobular Breast Carcinoma Interventions: Drug: 18F-fluorofuranylnorprogesterone; Device: Liquid Biopsy; Device: Positron Emission Tomography/Computed Tomography Sponsors: University of Wisconsin, Madison Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Interventions: Drug: Giredestrant; Drug: Fulvestrant; Drug: Abemaciclib; Drug: Palbociclib; Drug: Ribociclib; Drug: LHRH Agonist; Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx) Sponsors: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Conditions: Breast Cancer; Endocrine Therapy; CDK4/6 Inhibitors; Subsequent Treatment Intervention: Drug: Different treatment regimens following progression on CDK4/6 inhibitors. Sponsor: Hunan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
